Last reviewed · How we verify
NCT04953741
A Comparative Study on the Efficacy of Different Stepping-down Therapy for Childhood Asthma
Phase 4 trial testing Fluticasone propionate inhaled aerosol in Asthma in Children in 90 participants. Status unknown.
1 August 2022
Quick facts
| Lead sponsor | Xijing Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 1 August 2021 |
| Primary completion | 1 August 2022 |
| Estimated completion | 1 August 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Fluticasone propionate inhaled aerosol — full drug profile →
Conditions studied
- Asthma in Children — all drugs for Asthma in Children →
Sponsor
Xijing Hospital
Who can join
Adults 4 to 14, any sex, with Asthma in Children. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a 24-week, randomized, parallel group comparative effectiveness study to evaluate the risk of stepping down therapy for patients with well-controlled asthma treated with combination Inhaled corticosteroids (ICS) and Leukotriene receptor antagonist（LTRA).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04953741
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Asthma in Children
Currently open trials in the same condition.
- NCT06372249 — A Clinical Trial of Soluble Fiber for Asthma · Phase 2 · recruiting
- NCT07412769 — ASMact: Study on Management of Bronchial Asthma · recruiting
- NCT07138027 — SMART Implementation-Effectiveness Trial 2 · NA · recruiting
- NCT07137923 — SMART Implementation-Effectiveness Trial 1 · NA · recruiting
- NCT06851715 — Improving Quality of Life for Teenagers With Asthma · NA · recruiting
Other Xijing Hospital trials
Trials by the same sponsor.
- NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
- NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
- NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
- NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04953741 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
- Last refreshed: 8 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04953741.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing